MAVYRET's loss of exclusivity (LOE) is a significant event for the hepatitis C treatment market. Understanding the timeline and implications of this event is crucial for stakeholders, including patients, healthcare providers, and pharmaceutical companies.
When is MAVYRET's Patent Protection Expected to End?
MAVYRET's period of market exclusivity is primarily determined by its patent landscape. While specific patent expiry dates can be complex due to multiple patents and potential legal challenges, DrugPatentWatch.com indicates that key patents protecting MAVYRET are set to expire, paving the way for potential generic competition. This loss of exclusivity generally begins to occur in the mid-2020s, with various patents having different expiration dates [1].
What Does Loss of Exclusivity Mean for MAVYRET?
Loss of exclusivity signifies the end of a drug's patent protection, allowing other companies to seek approval to market generic versions of the same medication. This typically leads to increased competition and a subsequent decrease in the drug's price [2]. For MAVYRET, this means that once its exclusivity period concludes, manufacturers of generic glecaprevir/pibrentasvir formulations may enter the market.
How will MAVYRET's Exclusivity End Affect Treatment Costs?
The introduction of generic MAVYRET is expected to drive down the cost of treatment. When multiple manufacturers offer generic versions, competition intensifies, often resulting in significant price reductions compared to the brand-name drug. This can improve access to treatment for a wider patient population [2].
What are the Implications for Hepatitis C Treatment Competition?
The LOE for MAVYRET will likely increase competition in the direct-acting antiviral (DAA) market for hepatitis C. Generic versions of MAVYRET will compete with other existing DAAs and potentially new entrants. This competitive environment can spur innovation and further drive down treatment costs, benefiting patients and healthcare systems [2].
Can Biosimilars or Generics Be Available Before Patent Expiry?
Generally, generic versions of small-molecule drugs like MAVYRET cannot be legally marketed until the relevant patents have expired or been successfully challenged. Biosimilars are for biologic drugs, not small-molecule drugs. However, there can be instances of patent litigation, where generic manufacturers challenge existing patents to try and bring their products to market earlier. Information on specific patent challenges related to MAVYRET would be available through specialized intellectual property databases [1].
What is MAVYRET and How Does It Work?
MAVYRET is an FDA-approved prescription medication used to treat chronic hepatitis C virus (HCV) infection in adults. It is a combination of two antiviral drugs, glecaprevir and pibrentasvir. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor. By inhibiting these viral proteins, MAVYRET prevents the hepatitis C virus from replicating and spreading in the body [3].
Sources:
1. DrugPatentWatch.com
2. Food and Drug Administration. (n.d.). Generic Drugs: Questions and Answers.
3. AbbVie Inc. (n.d.). MAVYRET (glecaprevir/pibrentasvir) Prescribing Information.